Pegylated liposomal doxorubincin combined with ifosfamide as first-line treatment for patients with advanced or metastatic soft tissue sarcoma

刘　欣; 张晓伟; 王惠杰

doi:10.19401/j.cnki.1007-3639.2017.09.002

您当前的位置：

首页 >

文章列表页 >

Pegylated liposomal doxorubincin combined with ifosfamide as first-line treatment for patients with advanced or metastatic soft tissue sarcoma

更新时间：2025-12-31

- Pegylated liposomal doxorubincin combined with ifosfamide as first-line treatment for patients with advanced or metastatic soft tissue sarcoma
- China Oncology Vol. 27, Issue 9, Pages: 687-692(2017)
- 作者机构：
  
  复旦大学附属肿瘤医院肿瘤内科，复旦大学上海医学院肿瘤学系,上海,200032
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2017.09.002
  CLC：
- Published Online：27 September 2017，
  
  Published：27 September 2017
- 稿件说明：
移动端阅览
刘　欣,张晓伟,王惠杰,等. 聚乙二醇化脂质体多柔比星联合异环磷酰胺治疗晚期转移性软组织肉瘤[J]. 中国癌症杂志, 2017, 27(9): 687-692.

刘　欣, 张晓伟, 王惠杰. Pegylated liposomal doxorubincin combined with ifosfamide as first-line treatment for patients with advanced or metastatic soft tissue sarcoma[J]. China Oncology, 2017, 27(9): 687-692.
刘　欣,张晓伟,王惠杰,等. 聚乙二醇化脂质体多柔比星联合异环磷酰胺治疗晚期转移性软组织肉瘤[J]. 中国癌症杂志, 2017, 27(9): 687-692. DOI： 10.19401/j.cnki.1007-3639.2017.09.002.

刘　欣, 张晓伟, 王惠杰. Pegylated liposomal doxorubincin combined with ifosfamide as first-line treatment for patients with advanced or metastatic soft tissue sarcoma[J]. China Oncology, 2017, 27(9): 687-692. DOI： 10.19401/j.cnki.1007-3639.2017.09.002.

摘要

背景与目的：软组织肉瘤一旦出现远处转移，预后极差，中位生存时间不到1年。多柔比星联合异环磷酰胺(ifosfamide，IFO)(AI方案)是晚期软组织肉瘤常用的一线联合治疗方案。聚乙二醇脂质体多柔比星(pegylated liposomal doxorubicin，PLD)活性成分为盐酸多柔比星，药物包裹在脂质体中，可减少多柔比星的临床毒性反应。该研究探讨PLD联合IFO治疗晚期转移性软组织肉瘤的临床疗效和安全性。方法：选取晚期转移性软组织肉瘤患者25例，使用PLD联合IFO方案，PLD剂量30 mg/m

，静脉滴注，第1天；IFO剂量1.8 g/m

，静脉滴注，第1~5天；美司钠360 mg/m

，用IFO时0、4和8 h，21 d为1个周期。结果：所有患者化疗1~8个周期，中位周期数4。25例患者中部分缓解9例(36%)，疾病稳定12例(48%)，疾病进展4例(16%)，疾病控制率(完全缓解+部分缓解+疾病稳定)为84%(21/25)。中位无进展生存时间为7.3个月(95%CI：4.6~10.0个月)。由于失访病例较多，中位总生存时间未随访到。化疗后3/4级不良反应包括白细胞下降(20%)、粒细胞下降(28%)、贫血(4%)和呕吐(4%)。只有1例患者治疗过程中予以减量。结论：临床应用PLD联合IFO方案治疗晚期转移性软组织肉瘤疗效确切，且毒性反应较轻，值得进一步深入研究。

Abstract

Background and purpose: Patient with metastatic soft tissue sarcoma has a poor prognosis with median survival time of less than 1 year. Doxorubicin combined with ifosfamide (IFO) (AI regimen) is frequently used in the first-line treatment for patients with metastatic soft tissue sarcoma. Pegylated liposomal doxorubicin (PLD) is the liposomal formulation of doxorubicin and has exhibited less toxicity. Therefore our study was aimed to evaluate the efficacy and safety of PLD combined with IFO as the first-line treatment for pat

ients with advanced or metastatic soft tissue sarcoma (STS). Methods: A total of 25 chemotherapy-naive patients with advanced or metastatic STS were enrolled in this study between November 2013 and December 2015. All patients received treatment of PLD 30 mg/m

plus IFO 1.8 g/m

d1-5

repeatedly every 21 days. Results: All patients received 1-8 cycles of treatment

at a median of 4 cycles. Among 25 patients

partial response was observed in 9 patients (36%)

stable disease (SD) was observed in 12 patients (48%) and progressive disease (PD) in 4 patients (16%). The disease control rate (DCR

CR+PR+SD) was 84%. The median progression-free survival (PFS) was 7.3 months (95%CI

4.6 to 10.0 months). The grade 3/4 toxicities included leukopenia (20%)

neutropenia (28%)

anemia (4%) and vomiting (4%). Conclusion: Combination therapy comprising PLD and IFO was effective and well tolerated as first-line treatment for patients with advanced or metastatic STS

which warrants further research.

关键词

Keywords

references

Views

4015

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Surgical margin and efficacy evaluation of barrier resection for soft tissue sarcoma of extremities in 72 cases

Retrospective analysis of short-term efficacy and safety of preoperative radiotherapy for 33 cases of locally high-risk soft tissue sarcoma

Outcomes and prognostic factors of high-grade soft tissue sarcoma: experience at a single institution

Related Author

Shuai PENG

Kangwei WANG

Hongbo WANG

Hongqiang ZHANG

Xinglong QU

Yong CHEN

Ruming ZHANG

Guolun QU

Related Institution

Department of Oncosurgery, Minhang Branch, Fudan University Shanghai Cancer Center

Department of Bone and Soft Tissue Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University

Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai Key Laboratory of Radiation Oncology, Shanghai Clinical Research Center for Radiation Oncology

Department of Musculoskeletal Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University

Department of Pathology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Institute of Pathology, Fudan University

AI问答

⁰